The developer of anti microbial hygiene technologies, continues to make progress although it's still early days.
Discovered in 1999, Byotrol delivers broad spectrum, long lasting, anti microbial control. The technology has undergone nearly a decade of extensive testing by the world's major regulators and is now approved safe for use in the high need hygiene environments of healthcare, food production, animal welfare and the home. The results to date sound impressive.- At Monroe hospital the use of Byotrol as part of the hospital's disease control program has meant no hospital-acquired infection from the so-called super bugs (MRSA, C. difficile and VRE) in 2 years. - In food factories Byotrol has enabled already clean factories, to set new standards of hygiene frequently eliminating microbes completely from the food chain.- Even the cows are impressed! In over 250 dairy farm tests with over 170,000 dairy cows, Byotrol has made across the board improvements. Their farmers are reporting cleaner milk, better condition cows, and in many cases more milk!For the 6 months ended 30th September 2009 revenues increased to nearly £2m from £388k in the same period last year, with management acknowledging that the top line was boosted due to concerns about swine flu. The reported loss for the period was £590k (2008: loss of £1.4m). The balance sheet remains strong with cash, cash equivalents and receivables of £3.5m (2008:£1.5m), partly as a result of the fund raising undertaken in Autumn 2008.During the period the group successfully trialed Byotrol at Manchester Royal Infirmary where it performed on average 40% better than the current best available technology.2 new patent applications were filed as a result of innovations resulting from their R&D activities and new patent granted in Canada.The Chief Exec acknowledged that there is still much work to be done to achieve Byotrol’s true potential and visibility for the 4th quarter of the current financial year is still quite limited. There are bound to be a few hiccups on the way but with money in the bank to support commercialisation it all looks encouraging.
sEEMS ODD THAT IT IS GOING DOWN IN VALUE DOESN'T IT
